Potential involvement of tyrosine kinase pathway in the antagonist induced upregulation of the NMDA receptor NR2B subunit in cortical neurons.
The aim of this study was to study the potential mechanism(s) involved in the antagonist induced upregulation of the N-methyl-d-aspartate receptor (NMDA) NR2B subunit. The results show that chronic treatment of cortical neurons with tyrosine kinase inhibitor (genistein) resulted in downregulation of the NR2B subunit polypeptide levels, while daidzein, an inactive analog of genistein, did not alter the levels of NR2B subunit, implying that tyrosine kinases may be involved in the regulation of the NMDA NR2B subunit content. Chronic treatment of cortical neurons with the NMDA receptor antagonist, (+)-5-methyl-10,11-dihydro-5H-dibenzo[a, d]cycloheptane-5,10-iminemaleate (MK-801) enhanced the membrane associated tyrosine kinase activity and upregulated the NR2B receptor subunit. These results suggest that MK-801 induced upregulation of NMDA (NR2B) receptor subunit might be mediated by tyrosine kinases.